Ultimately, Chimerix’s board went with Jazz’s offer due to its cash payable nature and the recent downward trend in biopharma ...

Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has approved an amendment to its previously disclosed limited duration ...

The general mood among these heavyweight investors is divided, with 44% leaning bullish and 33% bearish. Among these notable options, 5 are puts, totaling $256,004, and 4 are calls, amounting to ...

Sino Biopharm has a good financial position. As of December 2024, it has CNY 9.6 billion in cash on hand and CNY 9.6 billion in debt. Total debt outstanding is 14.7% of its total assets. Its capital ...

Lynn Stockwell, the new Chief Executive Officer and Chairman of the Board of Directors of Bright Green Corporation, is also the CEO, Chair and sponsors and manages other NASDAQ listed corporations ...

Innate Pharma continues its slow rollout of promising clinical candidates, with 2025 set for key milestones. Read more about ...

HHS, a $1.6 trillion agency, includes the National Institutes of Health (NIH), the Centers for Disease Control and Prevention ...

The U.S. Health and Human Services Department is weighing plans to drastically cut federal government funding for domestic ...

Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...

During a health-focused event in New York on Tuesday, Google announced the development of a new collection of "open" AI ...

The inspection comes after a ProPublica investigation revealed that drugs made at the Glenmark Pharmaceuticals plant ...